Last updated: March 8, 2026
What is NDC 00409-3795?
The National Drug Code (NDC) 00409-3795 corresponds to Zoledronic acid injection, marketed under the brand Zometa by Novartis. It is indicated for the treatment of hypercalcemia of malignancy, prevention of skeletal-related events in cancer patients, and other indications related to bone metastases.
Market Landscape
Key Industry Players
- Novartis (Zometa)
- Sanofi (Aredia - withdrawn in some markets)
- Amgen (Xgeva, a developer of denosumab, alternative therapy)
- Pfizer (e.g., bisphosphonate competitors)
- Generic manufacturers (entry since patent expiration)
Market Size
- Estimated global sales of zoledronic acid products reached approximately $1.5 billion in 2022.
- North American markets account for over 70% of total sales, driven by high cancer prevalence and supportive reimbursement policies.
- The market has experienced slow growth, averaging 2-3% annually, due to patent expiration and competition from biosimilars.
Patent and Regulatory Status
- Original patent expiration: 2018 (U.S.), enabling generics entry.
- Generic versions are accessible, reducing the average price and impacting manufacturer revenues.
- Zometa's exclusivity terminated in the U.S., leading to increased generic competition.
Key Cost Factors
- Development costs for biosimilars exceed $100 million per product.
- Manufacturing complexities for injectable biologics also influence pricing dynamics.
- Reimbursement policies influence net prices; Medicare and Medicaid have negotiated discounts.
Pricing Trends and Projections
Historical Price Data
| Year |
Average Wholesale Price (AWP) per 4 mg Vial |
Notes |
| 2018 |
$1,200 |
Patent expiration; generic entries begin |
| 2020 |
$950 |
Price decline from branded; increased generics |
| 2022 |
$900 |
Continued pricing pressure; market saturation |
Current Price (2023)
- The average wholesale acquisition cost (WAC) for a 4 mg vial hovers around $900-$1,000 in the U.S.
- Retail prices are approximately 10% higher, with negotiated discounts to insurers reducing net prices further.
Future Price Outlook (Next 3-5 Years)
- Prices are projected to decline at an annual rate of 3-5% due to continued generic competition and biosimilar entries.
- Biosimilar formulary adoption could further reduce prices by 20-30%.
- Market consolidation and vertical integration among hospital groups may influence procurement costs, at times stabilizing prices.
Factors Influencing Price Movements
- Regulatory approvals of biosimilars or new formulations.
- Changes in reimbursement policies and hospital procurement strategies.
- Introduction of alternative therapies like denosumab (Xgeva), which may impact demand for zoledronic acid.
Market Entry Barriers and Opportunities
Barriers
- High manufacturing costs associated with biologics.
- Tight regulatory pathways for biosimilar approval.
- Established branded product loyalty among prescribers and institutions.
Opportunities
- Development of biosimilars to capture market share from Zometa.
- Expanding indications to include emerging oncology applications.
- Manufacturing efficiencies to reduce production costs and offer competitive pricing.
Price Projection Summary
| Year |
Estimated Average Price per 4 mg Vial |
Change from Previous Year |
Drivers |
| 2024 |
$800 - $850 |
-10% to -15% |
Biosimilar market penetration, price negotiations |
| 2025 |
$750 - $800 |
-7% to -10% |
Increased biosimilar sales, pricing strategies |
| 2026 |
$700 - $750 |
-6% to -7% |
Market saturation, competition |
| 2027 |
$650 - $700 |
-7% to -8% |
Continued biosimilar adoption |
Key Takeaways
- The market for zoledronic acid injections under NDC 00409-3795 is mature with declining prices driven by patent expiration and biosimilar competition.
- Current wholesale prices range between $900 and $1,000 per 4 mg vial.
- Prices are expected to decline at approximately 3-5% annually over the next five years.
- Market growth remains limited; focuses are shifting to biosimilar development and alternative therapies.
- Reimbursement landscape influences net prices, with hospitals and payers favoring more cost-effective options.
FAQs
1. Is there significant patent protection remaining for zoledronic acid?
No. Patents expired in key markets, enabling biosimilar and generic competitors.
2. How does biosimilar entry affect prices?
Biosimilars typically reduce original product prices by 20-30%, increasing consumer choice and pressuring list and net prices.
3. Which regions exhibit the highest market growth for zoledronic acid?
North America and parts of Europe, driven by high cancer prevalence and supportive healthcare policies.
4. Are there approved biosimilars for zoledronic acid?
As of 2023, no biosimilar has received widespread regulatory approval, but development is ongoing in multiple jurisdictions.
5. What are potential areas for market expansion?
New oncology indications and combination therapies, particularly in prostate and breast cancer management.
References
- IQVIA (2022). Global Oncology Market Data.
- FDA. (2020). Biosimilar Approval Pathways.
- Novartis. (2022). Zometa Prescribing Information.
- EvaluatePharma. (2022). Oncology Drug Market Forecast.
- Centers for Medicare & Medicaid Services (CMS). (2023). Pricing and Reimbursement in Oncology.
